About US
Contact us
-
Merck treads water in Q4 as Keytruda helps offset Remicade sufferingMerck & Co. ($MRK) took a one-two punch in the fourth quarter. Revenue from two top-selling franchises--JanuviaandRemicade--slid, dragging overall sales below analyst estimates at $10.2 billion. O2016/2/4
-
EMA validates Gilead’s Type II variation application for Truvada to reduce risk of HIV-1 infectionThe European Medicines Agency (EMA) has validated Gilead Sciences' Type II variation application for once-daily Truvada to reduce the risk of sexually acquired HIV-1 infection among uninfected adults2016/2/3
-
Allergan and AstraZeneca to develop ATM-AVI for antibiotic-resistant gram-negative infectionsIrish drug-maker Allergan has entered into a global agreement with UK's AstraZeneca to develop and commercialise ATM-AVI, an investigational, fixed-dose antibiotic combining aztreonam and avibactam.2016/2/3
-
New data boosts Novo against Sanofi in insulin-market fightNovo Nordisk ($NVO) has some new data in hand that could help a safety advantage make its way onto the label of new drugTresiba--and win it points against heavyweight rival Sanofi ($SNY). In a recent2016/2/2
-
Gilead scheduling meet-up with Massachusetts AG over hep C pricing: GlobeGilead Sciences ($GILD) is scheduling a meeting with Massachusetts Attorney General Maura Healey after last week's threat of legal action against the company. And though some legal experts doubt Heale2016/2/2
-
Merck sets $54K list price for hep C combo as it preps for battle with Gilead, AbbVieIndustry watchers have long been speculating on how Merck would take on heavyweights Gilead ($GILD) and AbbVie ($ABBV) when it priced its new hep C regimen. And now, they have their answer: Undercut t2016/2/1
-
Struggling Eisai gets FDA approval for cancer drug Halaven for liposarcomaJapan'sEisaigot a much-needed boost on Thursday when the FDA approved its cancer drug, Halaven, for treatment of liposarcoma for patients in which the cancer has advanced to the point where surgery is2016/2/1
-
Novartis CEO Jimenez sees U.S. pricing power draining awayRemember the days when drugmakers could raise prices without sparking political pushback? Novartis ($NVS) CEOJoe Jimenezdoes--and he says they're not coming back. "Those days are over," he said in aB2016/1/28
-
Lilly, BI approach CV-benefit label change for SGLT2 med JardianceEli Lilly ($LLY) andBoehringer Ingelheimare one step closer to an important label change for SGLT2 contenderJardiance. The FDA has accepted a supplemental New Drug Application that, if approved, will2016/1/28
-
FDA approves Allergan's Botox to treat lower limb spasticity in adultsThe US Food and Drug Administration (FDA) has granted approval for Allergan's Botox (onabotulinumtoxinA) to treat lower limb spasticity in adults to decrease the severity of increased muscle stiffness2016/1/27